[go: up one dir, main page]

MX2020004991A - Terapia oncológica mediante la degradación de la señalización dual de mek. - Google Patents

Terapia oncológica mediante la degradación de la señalización dual de mek.

Info

Publication number
MX2020004991A
MX2020004991A MX2020004991A MX2020004991A MX2020004991A MX 2020004991 A MX2020004991 A MX 2020004991A MX 2020004991 A MX2020004991 A MX 2020004991A MX 2020004991 A MX2020004991 A MX 2020004991A MX 2020004991 A MX2020004991 A MX 2020004991A
Authority
MX
Mexico
Prior art keywords
mek
resistance
kinases
drug
cleavage
Prior art date
Application number
MX2020004991A
Other languages
English (en)
Inventor
Paul J Hergenrother
Jessie Peh
Matthew Boudreau
Original Assignee
Univ Illinois
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Illinois filed Critical Univ Illinois
Publication of MX2020004991A publication Critical patent/MX2020004991A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/145—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/15—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

El descubrimiento de quinasas mutantes o de fusión que impulsan la oncogénesis, y la subsiguiente aprobación de inhibidores específicos para estas enzimas, ha sido crucial en el manejo de algunos cánceres. Sin embargo, la resistencia adquirida sigue siendo un problema significativo en la clínica, limitando la efectividad a largo plazo de la mayoría de estos fármacos. En la presente invención se demuestra una estrategia para vencer esta resistencia mediante la división de MEK inducida por fármacos (mediante la activación directa de procaspasa-3) combinada con la inhibición dirigida de quinasas. Se demuestra que este efecto de combinación es general en diversas histologías tumorales (melanoma, cáncer pulmonar y leucemia) y mutaciones impulsoras (BRAF o EGFR mutantes, quinasas de fusión EML4-ALK y BCR-ABL). La degradación mediada por caspasa-3 de quinasas MEK produce una inhibición sostenida de la vía, y esencialmente retarda o elimina la resistencia en células cancerosas de una forma superior a las combinaciones con inhibidores MEK. Estos datos sugieren que la generalidad de las divisiones quinasa MEK mediadas por fármacos es una estrategia terapéutica para prevenir la Resistencia a terapias anticancerosas dirigidas.
MX2020004991A 2017-11-17 2018-11-16 Terapia oncológica mediante la degradación de la señalización dual de mek. MX2020004991A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762587707P 2017-11-17 2017-11-17
PCT/US2018/061579 WO2019099873A1 (en) 2017-11-17 2018-11-16 Cancer therapy by degrading dual mek signaling

Publications (1)

Publication Number Publication Date
MX2020004991A true MX2020004991A (es) 2022-02-10

Family

ID=66538820

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020004991A MX2020004991A (es) 2017-11-17 2018-11-16 Terapia oncológica mediante la degradación de la señalización dual de mek.

Country Status (11)

Country Link
US (2) US11510919B2 (es)
EP (1) EP3710433A4 (es)
JP (1) JP7349155B2 (es)
KR (1) KR20200090771A (es)
CN (1) CN111491927A (es)
AU (1) AU2018368453B2 (es)
CA (1) CA3082575A1 (es)
IL (1) IL274663B2 (es)
MX (1) MX2020004991A (es)
SG (1) SG11202004384YA (es)
WO (1) WO2019099873A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019099873A1 (en) * 2017-11-17 2019-05-23 The Board Of Trustees Of The University Of Illinois Cancer therapy by degrading dual mek signaling
AU2019354771A1 (en) * 2018-10-05 2021-04-01 The Board Of Trustees Of The University Of Illinois Combination therapy for the treatment of uveal melanoma
AU2020283161A1 (en) * 2019-05-30 2022-01-06 The Board Of Trustees Of The University Of Illinois Procaspase-3 activation and immunotherapy for treatment of cancer
WO2023006088A1 (zh) * 2021-07-30 2023-02-02 浙江大学智能创新药物研究院 一种用于egfr激酶抑制剂的化合物、组合物及其应用

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4559157A (en) 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
LU84979A1 (fr) 1983-08-30 1985-04-24 Oreal Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
US4820508A (en) 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
US4992478A (en) 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
US5723459A (en) 1991-05-09 1998-03-03 Vertex Pharmaceuticals Incorporated Biologically active acylated amino acid derivatives
US5844001A (en) 1993-02-26 1998-12-01 Research Development Foundation Combination platinum chemotherapeutic/antiestrogen therapy for human cancers
FR2757866B1 (fr) 1996-12-30 2004-12-17 Catalyse Polymeres comportant des groupes ammoniums quaternaires, leur utilisation pour la fabrication d'un materiau a propretes antibacteriennes et leurs procedes de preparation
US6403765B1 (en) 1998-06-16 2002-06-11 Thomas Jefferson University Truncated Apaf-1 and methods of use thereof
US6303329B1 (en) 1998-07-27 2001-10-16 Pharmacia & Upjohn Company Method for autoactivation of procaspase 8
US6110691A (en) 2000-01-06 2000-08-29 Board Of Regents, The University Of Texas System Activators of caspases
US6608026B1 (en) 2000-08-23 2003-08-19 Board Of Regents, The University Of Texas System Apoptotic compounds
US20030008015A1 (en) 2000-10-11 2003-01-09 Levisage Catherine S. Polymer controlled delivery of a therapeutic agent
WO2002048329A2 (en) 2000-11-20 2002-06-20 Idun Pharmaceuticals, Inc. Membrane derived caspase-3, compositions comprising the same and methods of use therefor
WO2003024955A2 (en) 2001-09-18 2003-03-27 Sunesis Pharmaceuticals, Inc. Small molecule inhibitors of caspases
US20040180828A1 (en) 2003-01-30 2004-09-16 Yigong Shi Caspase-9 : BIR domain of XIAP complexes and methods of use
US7632972B2 (en) 2003-10-30 2009-12-15 The Board Of Trustees Of The University Of Illionis Compounds and methods for treatment of cancer and modulation of programmed cell death for melanoma and other cancer cells
CA2546920A1 (en) 2003-12-09 2005-06-23 Joel Moss Methods for suppressing an immune response or treating a proliferative disorder
US8440610B2 (en) 2004-11-12 2013-05-14 Massachusetts Institute Of Technology Mapkap kinase-2 as a specific target for blocking proliferation of P53-defective cells
CN101184491A (zh) 2005-05-26 2008-05-21 伊利诺伊大学评议会 包括活化半胱天冬酶-3酶原的癌细胞内选择性细胞凋亡诱导
US20070049602A1 (en) 2005-05-26 2007-03-01 The Board Of Trustees Of The University Of Illinois Selective Apoptotic Induction in Cancer Cells Including Activation of Procaspase-3
WO2008134474A2 (en) 2007-04-27 2008-11-06 The Board Of Trustees Of The University Of Illinois Compositions and methods including cell death inducers and procaspase activation
EP1896421B1 (en) 2005-06-23 2011-09-14 Merck Sharp & Dohme Corp. Benzocycloheptapyridines as inhibitors of the receptor tyrosine kinase met
ES2580108T3 (es) 2005-07-11 2016-08-19 Aerie Pharmaceuticals, Inc Compuestos de isoquinolina
TWI373473B (en) 2005-09-02 2012-10-01 Otsuka Pharma Co Ltd Anticancer agent
TW200803849A (en) 2005-09-16 2008-01-16 Schering Corp Pharmaceutical compositions and methods using temozolomide and a protein kinase inhibitor
US20070111936A1 (en) 2005-11-15 2007-05-17 Vladimir Pak Complex of alpha-fetoprotein and inducers of apoptosis for the treatment of cancer
EP2034828A4 (en) 2006-05-19 2011-04-06 Univ Illinois PHOSPHORUS COMPOUNDS WITH TRIPHENYL METHYL PHOSPHONATE TESTERS FOR THE TREATMENT OF MELANOMA OR OTHER TUMORS
TWI433674B (zh) 2006-12-28 2014-04-11 Infinity Discovery Inc 環杷明（ｃｙｃｌｏｐａｍｉｎｅ）類似物類
HUE030929T2 (en) 2007-07-20 2017-06-28 Nerviano Medical Sciences Srl Substituted indazole derivatives active as kinase inhibitors
RU2360692C1 (ru) 2007-12-21 2009-07-10 Тихоокеанский Институт Биоорганической Химии Дальневосточного Отделения Российской Академии Наук (Тибох Дво Ран) Средство, стимулирующее апоптоз клеток лейкемии человека
CA2711603A1 (en) 2008-01-11 2009-07-16 The Regents Of The University Of California Activators of executioner procaspases 3, 6 and 7
US20100291214A1 (en) 2008-12-23 2010-11-18 Armark Authentication Technologies, Llc Three-dimensional microfiber extrudate structure and process for forming three-dimensional microfiber extrudate structure
EP2393442A4 (en) 2009-02-09 2017-08-09 St. Jude Medical, Cardiology Division, Inc. Inflatable minimally invasive system for delivering and securing an annular implant
CN102438998A (zh) 2009-02-09 2012-05-02 伊利诺伊大学评议会 作为个性化抗癌药的胱天蛋白酶原活化化合物的设计、合成和评价
SG10201402287TA (en) 2009-05-11 2014-07-30 Berg Llc Methods for the diagnosis of metabolic disorders using epimetabolic shifters, multidimensional intracellular molecules, or environmental influencers
CA2763471A1 (en) 2009-05-27 2010-12-02 Cephalon, Inc. Combination therapy for the treatment of multiple myeloma
WO2010151746A2 (en) 2009-06-26 2010-12-29 Armark Authentication Technologies, Llc Three-dimensional microfiber extrudate structure and process for forming three-dimensional microfiber extrudate structure
TWI386203B (zh) 2011-01-07 2013-02-21 Univ China Medical 治療腦癌或用以降低腦癌細胞對替莫唑胺之抗藥性之醫藥組合物及其應用
WO2012118978A1 (en) 2011-03-03 2012-09-07 The Regents Of The University Of Colorado, A Body Corporate Methods for treating oncovirus positive cancers
WO2012178038A1 (en) 2011-06-24 2012-12-27 The Broad Institute, Inc. Methods of treating cancer
JP5427321B2 (ja) * 2011-07-27 2014-02-26 アストラゼネカ アクチボラグ ２−（２，４，５−置換−アニリノ）ピリミジン化合物
US8916705B2 (en) 2011-10-14 2014-12-23 The Board of Trustees of The University of Illilnois Procaspase-activating compounds and compositions
CA2865983C (en) 2012-03-02 2021-10-19 The Board Of Trustees Of The University Of Illinois Potent anticancer activity via dual compound activation
CA2866020C (en) 2012-03-06 2020-09-22 The Board Of Trustees Of The University Of Illinois Procaspase combination therapy for glioblastoma
BR112014022103B1 (pt) 2012-03-06 2022-04-19 The Board Of Trustees Of The University Of Illinois Composições e seus usos
JP6265558B2 (ja) 2012-08-03 2018-01-24 ザ ボード オブ トラスティーズ オブ ザ ユニヴァーシティー オブ イリノイ 酵素活性化化合物及び組成物
EP3800256A1 (en) 2012-11-06 2021-04-07 InteRNA Technologies B.V. Combination to be used in therapeutic use against diseases or conditions associated with melanoma, or in diseases or conditions associated with activated b-raf pathway
CN105163584B (zh) 2013-03-05 2019-06-04 田纳西大学研究基金会 用于治疗癌症的化合物
ES2822665T3 (es) 2013-05-31 2021-05-04 Merck Sharp & Dohme Terapias de combinación para el cáncer
CA2917742C (en) 2013-07-12 2020-04-14 Piramal Enterprises Limited A pharmaceutical combination for the treatment of melanoma
GB201320302D0 (en) * 2013-11-18 2014-01-01 Element Six Ltd Diamond components for quantum imaging sensing and information processing devices
CA2987340C (en) * 2015-06-05 2024-04-02 The Board Of Trustees Of The University Of Illinois Pac-1 combination therapy
JP7061068B2 (ja) 2015-12-18 2022-04-27 イグナイタ インコーポレイテッド 癌治療のための併用薬
WO2018106595A1 (en) 2016-12-05 2018-06-14 Fate Therapeutics, Inc. Compositions and methods for immune cell modulation in adoptive immunotherapies
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
WO2019099873A1 (en) * 2017-11-17 2019-05-23 The Board Of Trustees Of The University Of Illinois Cancer therapy by degrading dual mek signaling

Also Published As

Publication number Publication date
AU2018368453A1 (en) 2020-06-04
WO2019099873A1 (en) 2019-05-23
US12168006B2 (en) 2024-12-17
SG11202004384YA (en) 2020-06-29
JP7349155B2 (ja) 2023-09-22
IL274663B2 (en) 2024-01-01
CN111491927A (zh) 2020-08-04
EP3710433A4 (en) 2022-01-12
US20200276189A1 (en) 2020-09-03
US11510919B2 (en) 2022-11-29
JP2021503457A (ja) 2021-02-12
KR20200090771A (ko) 2020-07-29
CA3082575A1 (en) 2019-05-23
US20230158019A1 (en) 2023-05-25
EP3710433A1 (en) 2020-09-23
AU2018368453B2 (en) 2024-05-30
IL274663B1 (en) 2023-09-01
IL274663A (en) 2020-06-30

Similar Documents

Publication Publication Date Title
MX2020004991A (es) Terapia oncológica mediante la degradación de la señalización dual de mek.
Lamberti et al. Beyond EGFR, ALK and ROS1: current evidence and future perspectives on newly targetable oncogenic drivers in lung adenocarcinoma
McCubrey et al. Roles of signaling pathways in drug resistance, cancer initiating cells and cancer progression and metastasis
De Cian et al. Targeting telomeres and telomerase
Shaw et al. Phase III study of crizotinib versus pemetrexed or docetaxel chemotherapy in patients with advanced ALK-positive non-small cell lung cancer (NSCLC)(PROFILE 1007)
Ryan et al. Final overall survival (OS) analysis of COU-AA-302, a randomized phase 3 study of abiraterone acetate (AA) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) without prior chemotherapy
AU2018256477A1 (en) Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or AHI1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof
WO2019197605A3 (en) Drug combinations for use in the treatment of ras-mutant cancer
Yang et al. The role of the deubiquitinating enzyme DUB3/USP17 in cancer: a narrative review
Michetti et al. Mechanistic insights and therapeutic strategies for targeting autophagy in pancreatic ductal adenocarcinoma
Ou et al. Phase I/II dose-finding study of crizotinib (CRIZ) in combination with erlotinib (E) in patients (pts) with advanced non-small cell lung cancer (NSCLC)
WO2008088855A3 (en) Gene polymorphisms as predictors of tumor progression and their use in cancer therapy
WO2007132156A3 (en) Materials and methods relating to cancer diagnosis, prognosis and treatment based on the determination of novel molecular markers in tumors
NO20084635L (no) Fosfor inneholdende forbindelser inkludert trifenylmetylfosfonat estere for behandlingen av melanoma og andre kreftformer
Patergnani et al. Targeting the Wnt/β-catenin signaling pathway in cancer
Berghoff et al. How I treat anaplastic glioma without 1p/19q codeletion
Butkiewicz et al. Marszałek-Ze nczak, M.; Suwi nski, R. Polymorphisms in EGFR Gene Predict Clinical Outcome in Unresectable Non-Small Cell Lung Cancer Treated with Radiotherapy and Platinum-Based Chemoradio-therapy
Cross et al. Targeting Resistance in Egfr-Mutant Non-Small Cell Lung Cancer (Nsclc): Preclinical Evidence Supporting the Combination of Egfr Tyrosine Kinase Inhibitors (Tkis) Azd9291 and Gefitinib with Molecularly Targeted Agents and Immunotherapeutics
Yasuhiro et al. Development of an Axl/Mer dual inhibitor, ONO-9330547: promising single agent activity in an acute myeloid leukemia (AML) model
Endo et al. Phase II study of preoperative radiotherapy combined with S-1 plus cisplatin in clinically resectable type 4 or large type 3 gastric cancer: OGSG1205
Juncker-Jensen et al. PD-1 and LAG-3 synergize to drive tumour-infiltration of T cytotoxic cells in NSCLC tumours
Zhou et al. C-Jun regulates ER stress signaling to promote chemotherapy resistance in acute myeloid leukemia
Khasanov et al. Remote Results of Intraarterial Chemotherapy with Local Hyperthermia in the Treatment of Patients with Nasal and Paranasal Sinuses Cancer
Sharma et al. We shall overcome (drug resistance) some day
Boshoff Keynote Address V: Towards Personalized Treatment for Head and Neck Cancer